CALL US 1300 762 532

Clinical Trial Pathways

Cannabidiol in oral, oral mucosal and sublingual formulations preparations for therapeutic use when:

01

The cannabidiol is either plant derived, or when synthetic only contains the (-) CBD enantiomer

02

The maximum recommended daily dose is 150 mg or less of cannabidiol

03

In packs containing not more than 30 days’ supply

04

Cannabidiol comprises 98% or more of the total cannabinoid content of the preparation

05

Any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation

06

For adults aged 18 years and over

07

Packed in blister or strip packaging or in a container fitted with a child-resistant closure

We’d love to catch up with you to discuss what you want to achieve. Give us a call or drop us a line.